Zetta Venture Partners

Zetta Venture Partners is a San Francisco-based seed and early-stage venture firm with a singular focus: leading investments in pre-traction, AI-first companies with B2B business models. Founded in 2013 by Mark Gorenberg, an industry veteran formerly of Hummer Winblad, and now led by managing directors Mark Gorenberg, Ash Fontana, and Jocelyn Goldfein, the firm has been one of the earliest and most consistent thesis-driven AI-first investors in the venture community. Zetta announced its third fund of $180 million in 2020 and continues to invest with a clear mandate: write the first institutional check in B2B AI companies, frequently when the company has predictive models and early customers but limited revenue, and partner with founders specifically on the unique challenges of building AI-first companies, including data acquisition, machine learning team building, and predictive system commercialization.

The partnership operates with a small senior team where all three managing directors have been entrepreneurs and operators in addition to investors. Mark Gorenberg has anchored the firm since launch and has framed the next wave of AI as systems that create and understand complex domains including environmental systems, human biology, cybersecurity, and the global economy. Ash Fontana has been the public face of Zetta’s AI-native company-building thesis and has written and spoken extensively about the operational specifics of running AI-first companies. Jocelyn Goldfein, who joined as a managing director, brings deep technical and engineering leadership experience from Facebook, VMware, and other operating roles. The team operates with a thesis-driven concentration: 36 plus core companies in the portfolio across the firm’s history, including Kaggle (acquired by Google), Domo (IPO), Clearbit, Domino Data Lab, Tractable, and Invenia.

Zetta is not a healthcare specialist, but its AI-first B2B thesis intersects naturally with healthcare AI, computational biology, and clinical and operational AI applications. The firm has invested in companies whose AI-first technology applies to healthcare workflows, pharmaceutical development, and life sciences, and Gorenberg’s articulated thesis explicitly cites human biology as one of the next domains for AI systems. Founders building AI-first B2B companies for healthcare, particularly those with proprietary data assets, defensible model architectures, and clear enterprise customer wedges, fit the Zetta thesis cleanly.

Check sizes typically run from $1 million to $3 million at seed and pre-seed, with the capacity to lead at both stages and to follow on into Series A and selectively Series B. Zetta is decisively a seed-stage firm; it does not write growth-stage checks and is not a fit for founders looking for late-stage or growth capital. The firm leads almost all its rounds and almost always takes a board seat at the round it leads. Geographic scope is United States with a Bay Area concentration and selective international deals.

Founders who should approach Zetta are technical AI and machine learning founders building B2B AI-first companies, particularly those with proprietary data acquisition strategies, defensible model architectures, and a clear enterprise wedge. For healthcare AI, the firm is well suited for founders building AI-first applications and infrastructure for clinical workflows, pharmaceutical R&D, life sciences operations, and adjacent enterprise healthcare categories. Founders building consumer AI, B2C healthcare apps, therapeutics-only companies without an AI thesis, or pure healthcare services should pitch other firms. Zetta is decisively an AI-first B2B firm; its bar is technical and operational fit with the AI-native company-building thesis.

Entry path runs through warm introductions from portfolio CEOs, peer AI investors, and the broader AI research and operating communities. The senior team is publicly active at AI conferences, machine learning summits, and major venture events, and Ash Fontana in particular has been a prolific writer and speaker on AI-first company building. Cold inbound through the website is read and the firm has a relatively open posture toward direct outreach, particularly when the founder has a strong technical signal.

In a pitch, lead with the AI thesis, the data strategy, the model architecture, and the enterprise wedge. Zetta partners think specifically about how AI-first companies build defensible advantages through data network effects, model improvement loops, and enterprise integration, and they want to see why your company has a structural advantage rather than a temporary lead. They will probe your data acquisition strategy, your team’s machine learning capabilities, your enterprise sales motion, and your unit economics in detail. The firm’s added value is uniquely focused on the AI-native operational challenges that few generalist seed firms understand: data labeling and acquisition, ML team hiring, model deployment and monitoring, and the specific commercial dynamics of selling predictive systems to enterprises. Founders building AI-first B2B healthcare applications with proprietary data and defensible model strategies will find Zetta one of the most thesis-aligned and operationally focused tier-one seed partners in the AI healthcare category.